Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mediwound Ltd Ord Sh (MDWD)

Mediwound Ltd Ord Sh (MDWD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 163,113
  • Shares Outstanding, K 9,284
  • Annual Sales, $ 18,690 K
  • Annual Income, $ -6,720 K
  • 60-Month Beta 0.83
  • Price/Sales 10.70
  • Price/Cash Flow N/A
  • Price/Book 9.38
Trade MDWD with:

Options Overview Details

View History
  • Implied Volatility 65.67% ( -7.37%)
  • Historical Volatility 58.44%
  • IV Percentile 46%
  • IV Rank 46.46%
  • IV High 135.05% on 09/09/24
  • IV Low 5.47% on 11/14/23
  • Put/Call Vol Ratio 3.00
  • Today's Volume 8
  • Volume Avg (30-Day) 79
  • Put/Call OI Ratio 1.39
  • Today's Open Interest 2,484
  • Open Int (30-Day) 2,131

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.48
  • Number of Estimates 3
  • High Estimate -0.46
  • Low Estimate -0.49
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.25 +8.18%
on 09/09/24
20.55 -14.45%
on 08/27/24
-1.59 (-8.29%)
since 08/19/24
3-Month
12.78 +37.56%
on 06/21/24
24.00 -26.75%
on 07/05/24
+2.99 (+20.49%)
since 06/18/24
52-Week
7.45 +135.97%
on 11/09/23
24.00 -26.75%
on 07/05/24
+8.24 (+88.22%)
since 09/19/23

Most Recent Stories

More News
MediWound: Q2 Earnings Snapshot

MediWound: Q2 Earnings Snapshot

MDWD : 17.88 (+1.76%)
MediWound: Q1 Earnings Snapshot

MediWound: Q1 Earnings Snapshot

MDWD : 17.88 (+1.76%)
MediWound: Q4 Earnings Snapshot

MediWound: Q4 Earnings Snapshot

MDWD : 17.88 (+1.76%)
MediWound: Q3 Earnings Snapshot

MediWound: Q3 Earnings Snapshot

MDWD : 17.88 (+1.76%)
MediWound: Q2 Earnings Snapshot

MediWound: Q2 Earnings Snapshot

MDWD : 17.88 (+1.76%)
MediWound: Q1 Earnings Snapshot

MediWound: Q1 Earnings Snapshot

MDWD : 17.88 (+1.76%)
MediWound: Q4 Earnings Snapshot

MediWound: Q4 Earnings Snapshot

MDWD : 17.88 (+1.76%)
MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates

Positive Results in Two Phase 2 Trials of EscharEx FDA Assigned PDUFA Target Date of January 1, 2023 for NexoBrid BLA Enhanced the Board and Leadership...

MDWD : 17.88 (+1.76%)
MediWound Enhances Its Board and Executive Leadership Team

Mr. Nachum Shamir appointed as Chairman of the Board Dr. Robert Snyder appointed as Chief Medical Officer YAVNE, Israel, Aug. 08, 2022 (GLOBE NEWSWIRE)...

MDWD : 17.88 (+1.76%)
MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

Prescription Drug User Fee Act (PDUFA) target date of January 1, 2023...

MDWD : 17.88 (+1.76%)

Business Summary

MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue...

See More

Key Turning Points

3rd Resistance Point 19.61
2nd Resistance Point 19.19
1st Resistance Point 18.38
Last Price 17.88
1st Support Level 17.15
2nd Support Level 16.72
3rd Support Level 15.91

See More

52-Week High 24.00
Last Price 17.88
Fibonacci 61.8% 17.68
Fibonacci 50% 15.73
Fibonacci 38.2% 13.77
52-Week Low 7.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar